AnnetteFOkaiMD

Neurology • Plano, TX

Neuroimmunology/Multiple Sclerosis

Director, Neuroimmunology and Multiple Sclerosis Research North Texas Institute of Neurology and Headache

Join to view full profile

Dr. Okai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Okai's full profile

Already have an account?

Office
6201 Dallas Parkway
ste 100
Plano, TX 75024
Phone+1 972-403-4148

Summary

Dr. Annette Okai is a neurologist fellowship trained in Multiple Sclerosis in Dallas, TX. She received her medical degree from Drexel University College of Medicine/Hahnemann University and has been in practice 13 years. She is experienced in multiple sclerosis, neurology, and clinical trials. She has more than 10 publications and over 50 citings.

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Neuroimmunology & Multiple Sclerosis, 2006 - 2008
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Neurology, 2003 - 2006
Pennsylvania Hospital of the University of Pennsylvania Health SystemInternship, Internal Medicine, 2002 - 2003
Drexel University College of MedicineClass of 2002

Certifications & Licensure

TX State Medical License 2008 - 2026
DE State Medical License 2007 - 2025
PA State Medical License 2002 - 2024
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry

Clinical Trials

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Start of enrollment: 2017 Sep 19
Completed
Phase 3
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial Start of enrollment: 2018 May 02
Recruiting
Not Applicable
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Start of enrollment: 2019 Nov 18
Active, not recruiting
Phase 3
Cladribine Tablets After Treatment With Natalizumab (CLADRINA) Start of enrollment: 2020 Feb 19
Active, not recruiting
Phase 4
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab. Start of enrollment: 2020 Jul 30
Active, not recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

22 citations
Real-World Safety and Effectiveness of Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 3-Year Results from ESTEEM.
Mitzi J. Williams, Lilyana Amezcua, Annette Okai, Darin T. Okuda, Stanley Cohan
Neurology and Therapy. 2020-05-29
2 citations
Real-World Safety and Effectiveness After 5 Years of Dimethyl Fumarate Treatment in Black and Hispanic Patients with Multiple Sclerosis in ESTEEM.
Mitzi J Williams, Lilyana Amezcua, Angel Chinea, Stanley Cohan, Annette Okai
Neurology and Therapy. 2023-10-01
7 citations
Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database
Regina Berkovich, Edward Fox, Annette Okai, Yao Ding, Magdaliz Gorritz
Journal of Medical Economics. 2021-01-01

Press Mentions

Virtual AAN Meeting Features Reports on MS Symptoms, COVID-19, Health Disparities, Emerging Therapies, and MoreApril 27th, 2021
MSAA Events Focus on Mind-Body Connection to Mark MS Awareness MonthMarch 11th, 2020
MS Progression Focus of MSAA Events, ‘Ask Experts’ Sessions for Awareness MonthAugust 30th, 2018
Join now to see all